Weng H.-J.Wang T.-S.TSEN-FANG TSAI2020-10-222020-10-2220180007-0963https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044199795&doi=10.1111%2fbjd.16252&partnerID=40&md5=b719dd27f3537ab6325becfb6ce95c6ahttps://scholars.lib.ntu.edu.tw/handle/123456789/517562[SDGs]SDG3cyclosporine; etretin; methotrexate; secukinumab; ustekinumab; dermatological agent; monoclonal antibody; secukinumab; disease burden; disease clearance; diseases; drug effect; drug efficacy; erythrodermic psoriasis; human; Letter; phototherapy; priority journal; relapse; treatment duration; treatment failure; treatment response; adult; female; male; psoriasis; treatment outcome; Adult; Antibodies, Monoclonal; Dermatologic Agents; Female; Humans; Male; Psoriasis; Treatment Outcomeletter10.1111/bjd.16252292651752-s2.0-85044199795